ChiCTR2200063999 版本V1.2 版本创建时间2023/04/23 22:23:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200063999 

最近更新日期:

Date of Last Refreshed on:

2023-04-14 14:23:00 

注册时间:

Date of Registration:

2022-09-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

亚临床剂量艾司氯胺酮复合丙泊酚应用于宫腔镜的效果以及对术后睡眠质量的影响

Public title:

The effect of subclinical dose of esketamine combined with propofol on hysteroscopy and postoperative sleep quality

注册题目简写:

English Acronym:

研究课题的正式科学名称:

亚临床剂量艾司氯胺酮复合丙泊酚应用于宫腔镜的效果以及对术后睡眠质量的影响

Scientific title:

The effect of subclinical dose of esketamine combined with propofol on hysteroscopy and postoperative sleep quality

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

艾娟 

研究负责人:

艾娟 

Applicant:

Ai Juan 

Study leader:

Ai Juan 

申请注册联系人电话:

Applicant telephone:

+86 18565256215

研究负责人电话:

Study leader's
telephone:

+86 18565256215

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ajbbmm9@163.com

研究负责人电子邮件:

Study leader's E-mail:

ajbbmm9@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市番禺区大学城内环西路55号广东省中医院大学城医院麻醉科

研究负责人通讯地址:

广东省广州市番禺区大学城内环西路55号广东省中医院大学城医院麻醉科

Applicant address:

55 Inner Ring Road West, University City, Panyu District, Guangzhou, Guangdong

Study leader's address:

55 Inner Ring Road West, University City, Panyu District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院大学城医院麻醉科

Applicant's institution:

Department of Anesthesiology, University Town Hospital, Guangdong Hospital of Traditional Chinese Medicine

研究负责人所在单位:

广东省中医院大学城医院麻醉科

Affiliation of the Leader:

University Town Hospital, Guangdong Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

广东省中医院伦理委员会ZF2022-275-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-09-15 00:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Li Xiaoyan

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 81887233转35943

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省中医院大学城医院

Primary sponsor:

University Town Hospital, Guangdong Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市番禺区大学城内环西路55号

Primary sponsor's address:

55 Inner Ring Road West, University City, Panyu District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院大学城医院

具体地址:

番禺区大学城内环西路55号

Institution
hospital:

University Town Hospital, Guangdong Hospital of Traditional Chinese Medicine

Address:

55 Inner Ring Road West, University City, Panyu District

经费或物资来源:

自筹

Source(s) of funding:

self-funded

研究疾病:

N/A  

Target disease:

N/A

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究亚临床剂量艾司氯胺酮复合丙泊酚镇静应用于宫腔镜的效果以及对患者术后睡眠质量的影响。  

Objectives of Study:

To explore the effect of subclinical dose of esketamine combined with propofol sedation on hysteroscopy and the effect on postoperative sleep quality of patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.拟行宫腔镜手术的患者;
2.年龄18-74岁;
3.美国麻醉医师协会(ASA)分级为 Ⅰ~Ⅲ级;
4.自愿参加并知情签字同意。

Inclusion criteria

1. Patients undergoing hysteroscopic surgery;
2. Aged 18-74 years;
3. American Society of Anesthesiologists (ASA) grade Ⅰ to Ⅲ;
4. Volunteer and sign informed consent.

排除标准:

1.对试验药物过敏;
2.长期使用镇痛药物、精神系统药物、抗凝药物及酒精滥用;
3.既往有异常手术麻醉恢复史及麻醉药物过敏史;
4.3个月内参加过其他药物试验;
5.癫痫、颅内压增高;
6.严重心、肝、肾、肺等重要器官疾病;
7.包括可能导致睡眠障碍的重大精神或非癌症疾病,如慢性心力衰竭和慢性阻塞性肺疾病;
8.使用已知影响睡眠的药物;
9.上夜班。

Exclusion criteria:

1. Allergic to experimental drugs;
2. Long-term use of analgesic drugs, psychotropic drugs, anticoagulant drugs and alcohol abuse;
3. History of recovery from abnormal operation and anesthesia and history of anesthesia drug allergy;
4. Participated in other drug trials within 3 months;
5. Epilepsy, increased intracranial pressure;
6. Serious diseases of heart, liver, kidney, lung and other vital organs;
7. Include major psychiatric or non-cancer conditions that can cause sleep disturbances, such as chronic heart failure and chronic obstructive pulmonary disease;
8. Use medications known to affect sleep;
9. Work night shifts.

研究实施时间:

Study execute time:

From 2022-09-23 00:00:00 To 2023-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-23 00:00:00 To 2023-11-30 00:00:00

干预措施:

Interventions:

组别:

艾司氯胺酮复合丙泊酚组

样本量:

20

Group:

Esketamine combined with propofol group

Sample size:

干预措施:

艾司氯胺酮复合丙泊酚

干预措施代码:

Intervention:

Esketamine combined with propofol

Intervention code:

组别:

舒芬太尼复合丙泊酚组

样本量:

20

Group:

Sufentanil combined with propofol group

Sample size:

干预措施:

舒芬太尼复合丙泊酚

干预措施代码:

Intervention:

Sufentanil combined with propofol

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院大学城医院 

单位级别:

三级甲等 

Institution
hospital:

University Town Hospital, Guangdong Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

睡眠质量

指标类型:

主要指标

Outcome:

sleep quality

Type:

Primary indicator

测量时间点:

术前一天,术后第一天,第七天,第30天

测量方法:

评分量表

Measure time point of outcome:

One day before operation, the first day after operation, the seventh day, and the 30th day

Measure method:

Rating scale

指标中文名:

丙泊酚用量

指标类型:

次要指标

Outcome:

Propofol dosage

Type:

Secondary indicator

测量时间点:

术后

测量方法:

记录患者麻醉过程中的丙泊酚用量

Measure time point of outcome:

Postoperative

Measure method:

Record the amount of propofol used by patients during anesthesia

指标中文名:

疼痛视觉模拟评分评分

指标类型:

次要指标

Outcome:

Visual Analogue Scale Score for Pain

Type:

Secondary indicator

测量时间点:

术前一天,术后离开恢复室时,术后第一天

测量方法:

Measure time point of outcome:

One day before operation, when leaving the recovery room after operation, the first day after operation

Measure method:

指标中文名:

患者满意度

指标类型:

次要指标

Outcome:

Patient satisfaction

Type:

Secondary indicator

测量时间点:

术后一天

测量方法:

评分量表

Measure time point of outcome:

One day after operation

Measure method:

Rating scale

指标中文名:

改良ALDRETE苏醒评分

指标类型:

次要指标

Outcome:

Improved ALDRETE Awakening Score

Type:

Secondary indicator

测量时间点:

离开恢复室即刻

测量方法:

Measure time point of outcome:

Immediately after leaving the recovery room

Measure method:

指标中文名:

改良观察者警觉/镇静量表(MOAA/S)镇静评分

指标类型:

次要指标

Outcome:

Modified Observer Alert/Sedation Scale (MOAA/S) Sedation Score

Type:

Secondary indicator

测量时间点:

麻醉诱导后每隔5 min

测量方法:

Measure time point of outcome:

Every 5 minutes after anesthesia induction

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood pressure

Type:

Secondary indicator

测量时间点:

术中

测量方法:

血压计

Measure time point of outcome:

Intraoperative

Measure method:

Sphygmomanometer

指标中文名:

血氧饱和度

指标类型:

次要指标

Outcome:

Blood oxygen saturation

Type:

Secondary indicator

测量时间点:

术中

测量方法:

血氧饱和度仪

Measure time point of outcome:

Intraoperative

Measure method:

Blood oxygen saturation meter

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

Adverse reaction

Type:

Secondary indicator

测量时间点:

术后

测量方法:

观察评估

Measure time point of outcome:

Postoperative

Measure method:

Observation and evaluation

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 74 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由计算机生成随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number generated by computer

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-09-23 00:42:44